Cubist Pharmaceuticals
Biotech · Acquired
Daptomycin and novel antibiotics for drug-resistant bacterial infections
cubist.com →- Grants
- $5.7M
- 21 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 20 granted · 20 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓199419961998200020022004
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 5 same day | Department of Health and Human Services · Phase II · Inhibiting Pneumocystis Carinii's Growth--a New Therapy | $382,084 | |
| Federal grant· 2 of 5 same day | Department of Health and Human Services · Phase I · Inhibiting Pneumocystis Carinii Growth--a New Therapy | $100,000 | |
| Federal grant· 3 of 5 same day | Department of Health and Human Services · Phase II · Inhibiting Pneumocystis Carinii's Growth--a New Therapy | $367,916 | |
| Federal grant· 4 of 5 same day | Department of Health and Human Services · Phase II · Novel Drug Development Strategy For M Tuberculosis | $275,601 | |
| Federal grant· 5 of 5 same day | Department of Health and Human Services · Phase I · Novel Drug Development Strategy For M Tuberculosis | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development Of New Antibiotics | $100,000 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase I · Development Of A Screen For Bacterial Rnase P Inhibitors | $100,000 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase II · Bacterial Ribonuclease P Inhibitors As Novel Antibiotics | $508,077 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase II · Bacterial Ribonuclease P Inhibitors As Novel Antibiotics | $424,463 | |
| Federal grant | Department of Health and Human Services · Phase I · Development Of A Novel Target For Antimicrobial Drug | $100,000 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase II · Development of SecA as an Antimicrobial Target | $480,478 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase I · Development Of Seca For Antimicrobial Drug Discovery | $100,000 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase II · Development of SecA as an Antimicrobial Target | $530,161 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A Novel Target-based Drug Development Program | $119,941 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel Targets In A Drug Development Program | $99,800 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibitors of KD08-Phosphate Synthase as Antibiotics | $208,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibitors of Bacterial Undecaprenyl DiphosphateSynthase | $258,814 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase I · Modification of daptomycin by combinatorial biosynthesis | $258,205 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase II · Modification of Daptomycin by Combinatorial Biosynthesis | $500,000 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase II · Modification of Daptomycin by Combinatorial Biosynthesis | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Structure activity relationships around lipopeptides | $236,300 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1673 | Shire Pharmaceuticals | — | — |
| 1674 | PHOTOCHEM TECHNOLOGIES, LLC | — | — |
| 1675 | Deep Creek Pharma, LLC | — | — |
| 1676 | Cubist Pharmaceuticals | — | — |
| 1677 | Orphi Therapeutics Inc | — | — |
| 1678 | Myovant Sciences | — | — |
| 1679 | ROKE BIOTECHNOLOGIES LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Lipopeptide Compositions And Related Methodsgranted
- High Purity Lipopeptidesgranted
- Ceftolozane-tazobactam Pharmaceutical Compositionsgranted
- Tazobactam Arginine Antibiotic Compositionsapplication
- Lipopeptide Compositions And Related Methodsgranted
- Crystalline Form Of A Beta-lactamase Inhibitorgranted
- Beta-lactamase Inhibitorsgranted
- Methods For Preparing Purified Lipopeptidesapplication
- Cephalosporin Compositions And Methods Of Manufactureapplication
- Cephalosporin Compositions And Methods Of Manufacturegranted
- Beta-lactamase Inhibitorsgranted
- 1,3,4-OXADIAZOLE And 1,3,4-THIADIAZOLE Beta-lactamase Inhibitorsgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.